AI Summary
Nanobiotix secured approximately €86.1 million in a May follow-on, boosting cash runway into 2029 with €42.1 million on hand as of March 31, 2026. Phase 2 CONVERGE data for JNJ-1900 (NBTXR3) in unresectable Stage 3 NSCLC show high response rates and potential durability, while NANORAY-312 readout timelines may accelerate. Positive AACR preclinical Nanoprimer data further support broader platform potential.
Sentiment Rationale
Positive Phase 2 NSCLC data with high ORR/CRR and a strengthened balance sheet reduce near-term dilution risk and support potential re-rating. Historical parallels show such combos of strong data plus funding news can drive upside into milestone readouts, though execution risk remains high if subsequent data falters.
Trading Thesis
Bullish on NBTX over the next 6–12 months driven by strong NSCLC data and improved funding runway.
Market-Moving
- May 2026 follow-on €86.1m funding strengthens liquidity and burn runway.
- ESTRO 2026 NSCLC data show ORR 85.7% and CRR 57.1% in 7 patients.
- FDA amendment to NANORAY-312 may lead to earlier Phase 3 readouts.
- Nanoprimer AACR data suggest broader Nanobiotix platform upside.
Key Facts
- Follow-on offering completed in May 2026 for about €86.1m; includes pre-funded warrants.
- JNJ-1900 (NBTXR3) Phase 2 CONVERGE NSCLC data presented at ELCC and ESTRO 2026.
- ESTRO 2026 data show ORR 85.7% and CRR 57.1% in unresectable Stage 3 NSCLC.
- FDA accepted NANORAY-312 protocol amendment; earlier final analysis with fewer events.
- AACR preclinical data on Nanoprimer with LNP-DNA show improved safety and bioavailability.
Companies Mentioned
- Nanobiotix (NBTX): Subject of the release; Q1 2026 update includes funding and trial progress.
- Janssen Pharmaceutica NV (JNJ): Global co-development and commercialization license for JNJ-1900; ongoing collaboration.
Earnings
Category: Earnings and Corporate Developments. The release combines quarterly results with clinical advancement and funding updates, signaling near-term upside if trial data remain favorable and funding supports ongoing programs.